M&A expertise for regmed
19.12.2014 - Gil Beyen has been appointed independent director of Belgian biotech Novadip Biosciences, a spin-off from Louvain University and Saint-Luc University Hospital active in skeletal regenerative medicine.
Beyen is currently CEO and chairman of Erytech Pharma. Before that he served as CEO of French biotech Tigenix, which he also co-founded. In this capacity, he led the development and regulatory approval of ChondroCelect, the first Advanced Therapy Medicinal Product in Europe. He was also instrumental in the listing of the company and the subsequent merger with Cellerix. Beyen holds an MSc in Bio-Engineering from the University of Leuven and obtained an MBA from the University of Chicago in 1990.http://www.european-biotechnology-news.com/people/bio-people/2014/gil-beyen.html